Acebrophylline has been found to improve ciliary clearance, reduce the
frequency of episodes of bronchial obstruction, reduce the need for β2-
agonists and improve indices of ventilatory function.
Acebrophylline has early and positive effect on the quantity and viscosity
of expectoration and marked improvement symptoms of patients, with
favourable changes in respiratory function.
NAC is used in wide range of respiratory diseases due to its mucolytic and
anti-oxidant activities, making it attractive as a potential chronic
obstructive pulmonary disease therapy.
NAC therapy is a safe and effective modality that may reduce the decline
in the lung function of patients with Idiopathic Pulmonary Fibrosis.